Myasthenia Gravis Therapy
Mostrando 13-24 de 31 artigos, teses e dissertações.
-
13. Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis.
OBJECTIVE: The authors evaluated the response to extended cervicomediastinal thymectomy as a component of the integrated management of patients with myasthenia gravis in a large series of patients from a single institution. The authors evaluated the response to therapy with respect to a graded, multivariate, ordinal scale chosen to reflect the full range of
-
14. The long term experience of thymectomy for myasthenia gravis.
A retrospective survey of the records of 287 patients with generalised myasthenia gravis treated at New End Hospital and later at the Royal Free Hospital by anticholinesterase drugs, with or without thymectomy, between the years 1942 and 1976, shows that 62% of patients were improved. The timing of the operation, the grading of disease and the age and sex of
-
15. Autoimmune disease and the nervous system. Biochemical, molecular, and clinical update.
Autoimmunity in the central and peripheral nervous system can manifest as the result of cellular or humoral immune responses to autoantigens. There is evidence that multiple sclerosis is a cell-mediated autoimmune disease of the central nervous system in which both myelin and the cell that produces the myelin are destroyed. Diseases such as acute inflammator
-
16. Plasma exchange and immunosuppressive drug treatment in myasthenia gravis: no evidence for synergy.
We have investigated whether plasma exchange in myasthenia gravis synergises with additional immunosuppressive drug therapy (azathioprine, cyclophosphamide or cytosine arabinoside). Serum anti-acetylcholine receptor (AChR) antibody titres were followed over 28 days after a course of PE in 20 patients, of whom 17 were taking 20-80 mg prednisone on alternate d
-
17. Patient-specific anti=acetylcholine receptor antibody patterns in myasthenia gravis.
Anti-acetylcholine receptor (AChR) antibodies have been determined in the sera of ten myasthenic patients over a period of several months which in each case included a series of plasma-exchanges coupled with immunosuppressive therapy. The ratio of anti-(extra-junctional rat AChR): anti-(human AChR) antibody titres was found to vary with the patient but to be
-
18. Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis.
Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis. A patient who had developed all 5 is now described. The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patie
-
19. Treatment of ocular myasthenia with corticotrophin
Nine patients with severe myasthenia gravis, including ocular symptoms, who did not respond to anticholinesterase therapy were given prolonged courses of corticotrophin. In all patients except one there was an initial deterioration, sometimes necessitating assisted respiration, followed by a marked improvement which persisted for many weeks and occasionally
-
20. Thymectomy for myasthenia gravis
Between 1951 and 1971 thymectomy was performed on 41 patients with myasthenia gravis. They were selected from a total group of 95 myasthenic patients receiving anticholinesterase therapy. The criteria for selecting patients for thymectomy and the assessment of their progress after operation are described. All the patients have been examined by us at interval
-
21. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.
Myasthenia gravis (MG) and experimental autoimmune myasthenia gravis (EAMG) are caused, in part, by the production of autoantibodies against the main immunogenic region, amino acids 61-76, of the alpha chain of the acetylcholine receptor (AChR). Theoretically, induction of anti-idiotypic (Id) antibodies (Abs) should be a highly specific treatment for the dis
-
22. First report of subcutaneous phaeohyphomycosis of the foot caused by Phoma minutella.
Phoma minutella, a dematiaceous hyphomycete, was isolated to the exclusion of all other fungi from a subcutaneous inflammatory process on the foot of a farmer undergoing corticosteroid therapy for myasthenia gravis. Isolation was achieved on several nutrient media. Examination of stained smears and sections revealed dematiaceous fungal elements consistent wi
-
23. Immune complexes as therapy for autoimmunity
For several decades, intravenous Ig has been used as treatment for a variety of immune-related diseases, including immune thrombocytopenic purpura (ITP), autoimmune neuropathies, systemic lupus erythematosus, myasthenia gravis, Guillain-Barré syndrome, skin blistering syndromes, and Kawasaki disease. Despite years of use, its mechanism of immunomodulation i
American Society for Clinical Investigation.
-
24. Actuarial analysis of the occurrence of remissions following thymectomy for myasthenia gravis in 400 patients.
The role of thymectomy in the treatment of myasthenia gravis (MG) was analysed in 400 patients affected with generalised MG operated on between 1974-83, and prospectively followed up for five years after surgery. The occurrence of stable remission (SR) (that is, complete clinical drug-free remission that remains stable for all the subsequent follow up) was t